Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.

Abstract

OBJECTIVES:

To study the efficacy of allopurinol and benzbromarone to reduce serum urate concentrations in patients with primary chronic gout.

METHODS:

Prospective, parallel, open study of 86 consecutive male patients with primary chronic gout. Forty nine patients (26 normal excretors and 23 under excretors) were given allopurinol 300 mg/day and 37 under excretors benzbromarone 100 mg/day. After achieving steady plasma urate concentrations with such doses, treatment was then adjusted to obtain optimal plasmatic urate concentrations (under 6 mg/dl).

RESULTS:

Patients receiving allopurinol 300 mg/day showed a mean reduction of plasmatic urate of 2.75 mg/dl (from 8.60 to 5.85 mg/dl) and 3.34 mg/dl (from 9.10 to 5.76 mg/dl) in normal excretors and under excretors respectively. Patients receiving benzbromarone 100 mg/day achieved a reduction of plasmatic urate of 5.04 mg/dl (from 8.58 to 3.54 mg/dl). Fifty three per cent of patients receiving allopurinol and 100% receiving benzbromarone achieved optimal plasma urate concentrations at such doses. The patients with poor results with allopurinol 300 mg/day achieved a proper plasma urate concentration with allopurinol 450 to 600 mg/day, the mean final dose being 372 mg/day. Renal function improved and no case of renal lithiasis was observed among benzbromarone treated patients, whose mean final dose was 76 mg/day.

CONCLUSION:

Benzbromarone is very effective to control plasma urate concentrations at doses ranging from 50 to 100 mg/day. Uricosuric treatment is a suitable approach to the treatment of patients with gout who show underexcretion of urate.

• Authors: F Perez-Ruiz, A Alonso-Ruiz, M Calabozo, A Herrero-Beites, G García-Erauskin, E Ruiz-Lucea
• Journal: Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 57 Issue 9 Pg. 545-9 (Sep 1998) ISSN: 0003-4967 [Print] England
• PMID: 9849314 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Gout Suppressants
• Uricosuric Agents
• Uric Acid
• Benzbromarone
• Allopurinol

Topics

• Adult
• Aged
• Allopurinol (therapeutic use)
• Benzbromarone (therapeutic use)
• Chronic Disease
• Drug Administration Schedule
• Gout (blood, drug therapy)
• Gout Suppressants (therapeutic use)
• Humans
• Male
• Middle Aged
• Prospective Studies
• Uric Acid (blood)
• Uricosuric Agents (therapeutic use)